Story

LENZ Therapeutics Stock Jumps on Q2 Revenue Beat, Accelerating Sales

ENTHMSVIIDZHZH-TWJAKOHI
Aug 12, 20261 min read
LENZ Therapeutics Stock Jumps on Q2 Revenue Beat, Accelerating Sales
Text size
Background

Shares of LENZ Therapeutics jumped 7.7% in pre-market trading after the company released second-quarter 2026 financial results that significantly surpassed analyst expectations on both revenue and earnings per share.

Earnings Beat Drives Gains

For the second quarter, LENZ Therapeutics reported total revenue of $5.5 million, more than double the consensus forecast of approximately $2.5 million, according to its results published on the evening of August 11. The company's net loss was also narrower than anticipated at $1.02 per share, compared to an expected loss of $1.07 per share.

The strong top-line performance was driven by two key areas:

  • Product Revenue: $1.7 million from the sale of 27,000 monthly VIZZ packs, an increase of 9% from the previous quarter.
  • License Revenue: $3.8 million generated from international partnership agreements.

Commercial Momentum and Analyst Outlook

Sample IUX Markets – In-articleAd

Adding to investor optimism, LENZ management highlighted that commercial momentum is accelerating into the third quarter. The company reported that prescriptions for its VIZZ product surged 45% in July, a sign of strengthening market adoption that is not fully captured in the second-quarter figures.

Following the report, analysts at Citi reiterated their Buy rating on the stock but reduced their price target to $10 from $20, reflecting what the source material described as a more measured view of the commercial ramp-up. The broader Wall Street consensus remains constructive, with six Buy ratings and one Hold rating on the stock.

Market Context

The rally was also supported by a positive tone in the broader market, which often benefits smaller-capitalization biotech stocks. The advance provides a degree of relief for shareholders who have seen the stock fall from a 52-week high of $50.40 to a low of $4.68 prior to this rebound.

Read next

More on Stocks
Back to latest news

LATEST